25 results about "Ige binding epitopes" patented technology

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

Disclosed is an activator of regulatory T cells, an inhibitor of activity of effector T cells, an inhibitor of activation of B cells, an inhibitor of humoral immunity, or a therapeutic or prophylactic agent for an autoimmune disease, containing a polypeptide including an amino acid sequence equivalent to an HLA-DR binding epitope of an AChR.

The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure relates to recombinant T cell receptors capable of binding to NY-ESO-1 epitopes and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present application relates to the technical field of antibodies, in particular to a monoclonal antibody specifically targeting human SLC46A2 and application thereof. The present application expresses and purifies human SLC46A2 protein through a eukaryotic expression system; then uses the purified human SLC46A2 protein as an immunogen to immunize mice to produce antibodies; finally, a monoclonal antibody AB144 specifically recognizing and binding to human SLC46A2 protein is obtained through flow enrichment and screening, and the epitope recognized and bound by the antibody is identified; the complex structure of human SLC46A2-Fab144 is analyzed through cryo-EM to further determine the binding epitope of the antibody. It has been verified that the monoclonal antibody AB144 provided by the present application can specifically recognize and bind to the amino acid residues of human SLC46A2 protein, has high affinity, and can be used as a molecular tool for the detection of human SLC46A2 protein.

Some embodiments of the systems and methods provided herein relate to an assay. Some such embodiments include multiplex affinity probes and an antigen probe. multiplex affinity probes and an antigen probe Some embodiments include contacting a biological sample with the probes, wherein target binding agents such as antibodies in the biological sample compete away the multiplex affinity probes from binding to the antigen probe. Some such embodiments include detecting a decrease in binding of the multiplex affinity probes to the antigen probe, thereby indicating the presence or an amount of the target binding agents in the biological sample.

The invention discloses a neutralizing antibody targeting a filovirus host receptor NPC1 and an antibody fusion protein of a broad-spectrum neutralized filovirus and a mutant thereof, the neutralizing antibody is composed of a specific heavy chain and a specific light chain, can specifically bind to an NPC1-C structural domain of the host receptor NPC1 protein, has a clear binding epitope, still has binding activity in an endosome acidic environment, and can be used for preparing a recombinant filovirus. The light chain of the antibody fusion protein constructed on the basis of the neutralizing antibody contains NPC2 protein and flexible Linker, the antibody fusion protein has broad-spectrum neutralizing activity on high-pathogenicity filoviruses and mutant strains thereof, and a new thought and a new strategy are provided for research and development of anti-filovirus infection drugs; good application prospects and industrial conversion values are realized.

The present disclosure relates to recombinant T cell receptors capable of binding to NY-ESO-1 epitopes and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

This disclosure relates to a recombinant T-cell receptor capable of binding to the gp100 epitope and a nucleic acid molecule encoding said recombinant T-cell receptor. In some embodiments, the nucleic acid molecule further comprises a second nucleotide sequence, wherein said second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of endogenous TCRs. Other aspects of this disclosure relate to a vector comprising said nucleic acid molecule and a cell comprising said recombinant TCR, said nucleic acid molecule, or said vector. Other aspects of this disclosure relate to methods of using said recombinant TCR, said nucleic acid molecule, said vector, and said cell. In some embodiments, said methods include treating a subject with cancer in need.

The present disclosure provides an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof specifically binds to TSLP. The antibody of the present application can effectively inhibit the activation of TSLP on the STATs and JAK2 signaling pathway of H_TSLP Reporter Cell Line cells, and both the antibody of the present application and Tezepelumab can effectively inhibit the proliferation promoting effect of TSLP on BaF3-TSLPR / IL7Rα cells. The antibody of the present application does not cross the binding epitope of Tezepelumab, does not block the antibacterial peptide MKK34 with antibacterial activity at the C-terminus, and is expected to retain the ability of TSLP to resist bacterial infection from the outside.

The present disclosure relates to recombinant T cell receptors capable of binding to NY-ESO-1 epitopes and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure relates to recombinant T cell receptors capable of binding to a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

The present invention provides humanized versions of single-domain antibodies specifically binding the epitope tag of SRLEEELRRRLTE (SEQ ID NO: 2), which can be used for binding, detection, immobilization, isolation or purification a protein comprising the said epitope tag. Furthermore, the present invention relates to a nucleic acid encoding the humanized antibody and a vector comprising the nucleic acid, as well as a host cell comprising the nucleic acid or the vector described herein.

This disclosure relates to a recombinant T-cell receptor capable of binding to the gp100 epitope and a nucleic acid molecule encoding said recombinant T-cell receptor. In some embodiments, the nucleic acid molecule further comprises a second nucleotide sequence, wherein said second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of endogenous TCRs. Other aspects of this disclosure relate to a vector comprising said nucleic acid molecule and a cell comprising said recombinant TCR, said nucleic acid molecule, or said vector. Other aspects of this disclosure relate to methods of using said recombinant TCR, said nucleic acid molecule, said vector, and said cell. In some embodiments, said methods include treating a subject with cancer in need.

The invention is applicable to the technical field of biological medicines, and provides a single-antigen or multi-antigen mRNA vaccine for preventing or treating hepatitis B virus infection and application thereof. The protein coded by mRNA comprises a fusion protein (Pan-HLA-DR-epitope-preS1-Fc) formed by fusing a hepatitis B virus surface antigen and / or a hepatitis B virus front surface antigen 1 with a pan-HLA-DR binding epitope and a human IgG1 Fc segment. After mRNA is wrapped into a delivery system through lipid nanoparticles, a single-antigen or multi-antigen mRNA vaccine is prepared. The mRNA vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen and / or hepatitis B virus front surface antigen 1, and can be used for preventing and treating hepatitis B; all the components in the mRNA vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and good practical application value is achieved.

The present disclosure relates to recombinant T cell receptors capable of binding to a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present invention provides humanized versions of single domain antibodies that specifically bind to the epitope tag of SRLEEELRRRLTE (SEQ ID NO: 2), which can be used to bind, detect, immobilize, isolate or purify proteins comprising said epitope tag. Furthermore, the present invention relates to nucleic acids encoding said humanized antibodies and vectors comprising the nucleic acids, as well as host cells comprising the nucleic acids or vectors described herein.

Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from a subject involving the use of a capture antibody that binds to a tau epitope and a detection antibody that binds to an epitope comprising amino acid residues spanning the junction of exon 4 and exon 5 of CNS-derived tau.

The present disclosure relates to recombinant T cell receptors capable of binding to a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

The invention discloses a T cell receptor for specifically recognizing an HLA-A11 restricted EBV LMP2 epitope peptide and application of the T cell receptor. The invention relates to the field of biomedicine, and provides a T cell receptor for recognizing HLA-A11 restrictive LMP2373-381 epitope peptide, which comprises an alpha chain and a beta chain, the amino acid sequence of the CDR3 of the alpha chain is as shown in the 107th to 120th sites of SEQ ID NO: 2; the amino acid sequence of the CDR3 of the beta chain is as shown in 109th to 119th sites of SEQ ID NO: 4. According to the present invention, the TCR specifically recognizes and is combined with the LMP2373-381 epitope peptide / HLA-A11 compound, the corresponding TCR-T cell has the LMP2373-381 epitope peptide dependent human target cell killing ability, and the important application value is provided for the prevention and treatment of EBV infection.

The present invention provides humanized versions of single-domain antibodies specifically binding the epitope tag of SRLEEELRRRLTE (SEQ ID NO: 2), which can be used for binding, detection, immobilization, isolation or purification a protein comprising the said epitope tag. Furthermore, the present invention relates to a nucleic acid encoding the humanized antibody and a vector comprising the nucleic acid, as well as a host cell comprising the nucleic acid or the vector described herein.